ANRO — Alto Neuroscience Balance Sheet
0.000.00%
- $164.63m
- $39.16m
- 33
- 33
- 29
- 21
Annual balance sheet for Alto Neuroscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 25.7 | 48.3 | 82.5 | 168 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 1.74 | 0.546 | 0.112 | 0.03 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 27.7 | 49.2 | 85.4 | 169 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 1.06 | 1.58 | 1.23 | 7.7 |
| Other Long Term Assets | ||||
| Total Assets | 28.8 | 50.9 | 86.6 | 178 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 1.81 | 5.56 | 5.61 | 10 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 3.11 | 17 | 16.8 | 26.1 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 25.7 | 33.8 | 69.8 | 151 |
| Total Liabilities & Shareholders' Equity | 28.8 | 50.9 | 86.6 | 178 |
| Total Common Shares Outstanding | ||||
| Total Preferred Shares Outstanding |